Inventor

Austin L. Gurney

Inventor

Belmont, CA, US

Overview

1999–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 718 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides21%

A61KPreparations for medical, dental or toiletry purposes16%

C12NMicroorganisms or enzymes12%

G01NInvestigating or analysing materials by determining their chemical or physical properties12%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture9%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms8%

C07HSugars5%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations4%

A01KAnimal husbandry3%

PatentTitleYear

11,046,760Combination therapy for treatment of disease2021 10,730,940VEGF/DLL4 binding agents and uses thereof2020 10,544,219TIGIT-binding agents and uses thereof2020 10,232,017Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides2019 10,112,997Tight-binding agents and uses thereof2018 10,011,654Antibodies directed to IL-17A/IL-17F heterodimers2018 9,914,771'Method for making heteromultimeric molecules'2018 9,879,084'Modified immunoglobulin molecules that specifically bind human VEGF and DLL4'2018 9,873,726Methods for identifying and isolating cells expressing a polypeptide2018 9,850,311Compositions and methods for diagnosing and treating cancer2017 9,833,500Immunotherapy with binding agents2017 9,732,139'Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor'2017 9,724,390'Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents'2017 9,717,794'Compositions and methods for treating and diagnosing cancer'2017 9,676,865'Antibodies to a non-ligand binding region of at least two NOTCH receptors'2017 9,644,034'Anti-RSPO2 antibodies and uses thereof'2017 9,617,340'Compositions and methods for diagnosing and treating cancer'2017 9,610,348'Compositions and methods for treating and diagnosing cancer'2017 9,598,497'RSPO3 binding agents and uses thereof'2017 9,579,361'Wnt antagonist and methods of treatment and screening'2017 9,573,998'Antibodies against human FZD5 and FZD8'2017 9,574,009'Polynucleotides encoding VEGF/DLL4 binding agents'2017 9,505,832'Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3'2016 9,499,613'Notch1 receptor binding agents and methods of use thereof'2016 9,499,630'Frizzled-binding agents and uses thereof'2016 9,422,546'Methods for identifying and isolating cells expressing a polypeptide'2016 9,416,178'Jagged-binding agents and uses thereof'2016 9,376,497'Compositions and methods for diagnosing and treating cancer'2016 9,376,488'VEGF binding antibodies'2016 9,327,014'Immunotherapy with binding agents'2016 9,309,311'Method for making Heteromultimeric molecules'2016 9,273,139'Monoclonal antibodies against frizzled'2016 9,228,013'Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell'2016 9,228,020'Compositions and methods for diagnosing and treating cancer'2016 9,206,256'DDR1-binding agents and methods of use thereof'2015 9,181,333'RSPO3 binding agents and uses thereof'2015 9,168,300'MET-binding agents and uses thereof'2015 9,157,904'Wnt antagonists and methods of treatment and screening'2015 9,132,189'Notch1 binding agents and methods of use thereof'2015 9,109,025'Anti-RSPO2 antibodies'2015 9,109,024'Anti-RSPO1 antibodies and uses thereof'2015 9,067,986'Method for making heteromultimeric molecules'2015 9,040,044'Compositions and methods for treating and diagnosing cancer'2015 9,023,621'Methods for identifying and isolating cells expressing a polypeptide'2015 8,980,260'Monoclonal antibody that binds human notch2 and notch3'2015 8,975,044'Polynucleotides encoding for frizzled-binding agents and uses thereof'2015 8,945,878'Methods for identifying and isolating cells expressing a polypeptide'2015 8,945,874'Polynucleotides encoding NOTCH1 receptor antibodies'2015 8,945,873'Polynucleotides encoding Notch receptor antibodies'2015 8,945,547'Notch1 receptor antibodies and methods of treatment'2015 8,945,569'Jagged-binding agents and uses thereof'2015 8,921,106'Antibodies that bind the glutamate ligand binding region of NOTCH3'2014 8,883,736'Compositions and methods for treating and diagnosing cancer'2014 8,858,941'VEGF/DLL4 binding agents and uses thereof'2014 8,802,097'Anti-RSPO1 antibodies'2014 8,802,103'Compositions and methods for diagnosing and treating cancer'2014 8,784,811'Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1'2014 8,765,913'Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells'2014 8,652,472'Compositions and methods for diagnosing and treating cancer'2014 8,652,843'DDR1-binding agents and methods of use thereof'2014 8,642,740'Antibodies to lymphotoxin-alpha'2014 8,628,774'Compositions and methods for treating and diagnosing cancer'2014 8,551,789'Frizzled-binding agents and their use in screening for WNT inhibitors'2013 8,551,715'Methods for identifying and isolating cells expressing a polypeptide'2013 8,541,552'Antibodies to lymphotoxin-Î±'2013 8,540,989'Compositions and methods for treating and diagnosing cancer'2013 8,507,442'Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8'2013 8,460,661'Methods of using antibodies that bind the glutamate ligand binding region of Notch1'2013 8,455,217'Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof'2013 8,435,513'NOTCH1 receptor antibodies and methods of treatment'2013 8,425,903'Methods of treatment by administering antibodies to notch receptors'2013 8,404,237'Antibodies to the NOTCH1 receptor'2013 8,349,329'Antibodies that bind to PRO286'2013 8,350,008'WISP polypeptides and nucleic acids encoding same'2013 8,338,132'Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof'2012 8,324,361'Nucleic acid molecules encoding soluble frizzled (FZD) receptors'2012 8,287,869'Method of treating inflammatory disease by inhibition of IL-17 production'2012 8,226,943'Antibodies to notch receptors'2012 8,216,807'Antibodies to lymphotoxin-Î±'2012 8,206,713'Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2'2012 8,178,082'Methods for up-regulating PAP1 in animals suffering from pancreatic disorders'2012 8,158,758'Compositions and methods for treating and diagnosing cancer'2012 8,158,757'Compositions and methods for treating and diagnosing cancer'2012 8,106,156'PRO1120 polypeptides'2012 8,097,700'TAT294 polypeptides'2012 8,088,386'Treatment of complement-associated disorders'2012 8,088,617'Antibodies that bind the glutamate ligand binding region of Notch1'2012 8,084,200'Compositions and methods for the diagnosis and treatment of tumor'2011 8,075,888'Methods of treatment using antibodies to IL-17 homologous polypeptides'2011 8,063,186'Antibodies to PRO7436 polypeptides'2011 8,034,342'Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E'2011 8,007,798'Treatment of complement-associated disorders'2011 7,982,013'Frizzled-binding agents and uses thereof'2011 7,982,015'Compositions and methods for treatment of cancer'2011 7,939,263'Compositions and methods for treating and diagnosing cancer'2011 7,923,011'Antibodies to lymphotoxin-alpha'2011 7,919,092'Antibodies to notch receptors'2011 7,863,422'Anti-PRO87299 antibodies'2011 RE041888'Polynucleotide overexpressed in tumors'2010 7,807,385'Method of detecting PRO9917'2010 7,795,412'Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells'2010 7,786,272'Antibodies to PRO352'2010 7,777,007'PRO9907 antibodies'2010 7,771,719'Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E'2010 7,749,500'Antibodies to IL-17 polypeptides and therapeutic uses thereof'2010 7,750,124'Anti-human DLL4 antibodies and compositions'2010 7,741,056'Use of A33 antigens and JAM-IT'2010 7,728,108'PRO1550 polypeptides'2010 7,723,488'Monoclonal antibodies to secreted and transmembrane polypeptides'2010 7,723,112'Compositions and methods for treating and diagnosing cancer'2010 7,723,477'Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth'2010 7,718,397'Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof'2010 7,718,173'Anti-pro6094 antibodies'2010 7,718,770'PRO1305-polypeptides'2010 7,709,602'PRO1078 polypeptides'2010 7,709,603'PRO1190 polypeptides'2010 7,704,496'Antibodies against PRO1341 polypeptide'2010 7,700,736'PRO350 antibodies'2010 7,696,319'PRO1772 antibodies'2010 7,696,327'Antibodies to human Toll homologues'2010 7,691,978'Antibodies that bind TAT294'2010 7,691,566'Compositions and methods for treatment of cancer'2010 7,635,478'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2009 7,619,062'PRO214 polypeptides'2009 7,605,229'PRO87299 polypeptides'2009 7,601,514'Nucleic acid encoding PRO10268 polypeptides'2009 7,589,172'PRO256 polypeptides'2009 7,582,293'Anti-PRO6308 antibodies'2009 7,579,161'Assay methods for suppressor of fused modulation of hedgehog signaling'2009 7,576,182'Compositions and methods for the treatment of immune related diseases'2009 7,566,774'PRO4977 polypeptides'2009 7,563,867'PRO4356 polypeptides'2009 7,557,192'Anti-PRO335 antibodies'2009 7,550,573'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2009 7,547,507'Methods for the diagnosis of tumors'2009 7,544,482'Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof'2009 7,538,086'PRO1303 polypeptides'2009 7,534,856'PRO19624 antibodies'2009 7,524,497'Antibodies to PRO 1120 polypeptide'2009 7,521,539'Anti-PRO4989 antibodies'2009 7,514,538'Compositions and methods for the diagnosis and treatment of tumor'2009 7,510,709'Method of treating inflammatory disease by inhibition of IL-17 production'2009 7,507,557'Nucleic acids encoding PRO1375 polypeptides'2009 7,507,404'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2009 7,504,480'PRO10275 polypeptides'2009 7,504,484'Antibodies to the PRO1561 polypeptide'2009 7,495,083'PRO940 antibodies'2009 7,495,082'Antibodies to PRO4349 polypeptides'2009 7,491,529'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2009 7,491,797'PRO6308 polypeptide'2009 7,491,512'Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof'2009 7,488,796'PRO1269 polypeptides'2009 7,488,795'PRO846 polypeptides'2009 7,488,586'PRO4409 polypeptides'2009 7,479,544'Anti-PRO87299 antibodies'2009 7,479,545'PRO6001 antibodies'2009 7,476,723'Immunoconjugates and antibodies to PRO9917'2009 7,473,763'Receptor for IL-17 homologous polypeptides and uses thereof'2009 7,470,771'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,470,774'Anti-pro1477 antibodies'2008 7,468,427'Antibodies to PRO1275 polypeptide'2008 7,468,424'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,465,786'PRO1801 polypeptides'2008 7,465,785'Polypeptide encoded by a nucleic acid over-expressed in melanoma'2008 7,462,692'PRO1477 polypeptides'2008 7,456,261'PRO9830 antibodies'2008 7,452,975'Anti-PRO7168 antibodies'2008 7,449,551'PRO211 polypeptides'2008 7,449,549'PRO9822 polypeptides'2008 7,449,554'Antibodies against the PRO4977 polypeptides'2008 7,445,905'Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders'2008 7,442,772'Antibodies to PRO361 polypeptide'2008 7,442,765'Secreted transmembrane polypeptides and nucleic acids encoding the same'2008 7,439,325'PRO6001 polypeptides'2008 7,435,798'Antibodies to a polypeptide encoded by a nucleic acid overexpressed in normal stomach, normal skin and kidney tumor'2008 7,435,793'Peptides that induce chondrocyte redifferentiation'2008 7,432,345'PRO1475 polypeptide'2008 7,429,640'PRO6181 polypeptides'2008 7,429,641'PRO9830 polypeptides'2008 7,427,667'PRO9835 antibodies'2008 7,427,664'Antibodies to polypeptides that stimulate TNF-Î± release'2008 7,425,621'Antibodies against the PRO4401 polypeptide'2008 7,425,613'PRO1375 polypeptides'2008 7,425,605'PRO1486 polypeptides'2008 7,425,609'PRO4330 polypeptides'2008 7,423,119'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,423,120'PRO19814 polypeptides'2008 7,423,130'PRO1158 polypeptides'2008 7,423,127'Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma'2008 7,419,799'Compositions and methods for the treatment of immune related diseases'2008 7,419,663'Treatment of complement-associated disorders'2008 7,417,116'PRO7155 polypeptides'2008 7,417,123'PRO4399 Antibodies'2008 7,417,115'PRO6027 polypeptides'2008 7,417,126'PRO246 antibodies'2008 7,417,125'Antibodies that bind a PRO1158 polypeptide'2008 7,414,112'Antibodies to PRO1550 polypeptides'2008 7,411,037'Polypeptides encoded by a nucleic acid underexpressed in melanoma'2008 7,411,047'PRO6097 antibodies'2008 7,411,040'PRO6182 polypeptides'2008 7,408,035'PRO9864 polypeptides'2008 7,408,034'PRO20025 polypeptides'2008 7,408,033'PRO5995 polypeptides'2008 7,408,042'Anti-PRO6181 antibodies'2008 7,408,032'PRO1188 polypeptides'2008 7,405,269'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,405,268'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,402,656'PRO10013 polypeptides'2008 7,402,661'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,399,828'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,399,834'Anti-PRO1558 antibodies'2008 7,399,824'PRO19680 antibodies'2008 7,396,906'Pro4399 Polypeptides'2008 7,396,907'Antibodies that bind PRO6182 polypeptides'2008 7,396,916'Antibody to a polypeptide overexpressed in tumors'2008 7,393,532'Modulation of T cell differentiation for the treatment of T helper cell mediated diseases'2008 7,393,917'PRO1482 polypeptides'2008 7,393,931'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,390,883'PRO4428 antibodies'2008 7,390,887'Antibodies against PRO4330'2008 7,390,886'PRO9822 antibodies'2008 7,390,878'PRO6090 polypeptides'2008 7,390,486'PRO4381 antibodies'2008 7,390,876'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,390,877'PRO4381 polypeptides'2008 7,390,879'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,388,073'PRO9835 polypeptides'2008 7,385,031'PRO6097 polypeptides'2008 7,385,030'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,385,033'PRO12970 polypeptides'2008 7,381,791'PRO9739 polypeptides'2008 7,381,809'Compositions and methods for the treatment of immune related diseases'2008 7,378,486'PRO1482 antibodies'2008 7,378,507'PRO217 polypeptides'2008 7,378,491'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,378,501'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,378,502'PRO4389 antibodies'2008 7,378,487'PRO19675 polypeptides'2008 7,375,195'Anti-PRO7171 polypeptides'2008 7,375,184'PRO1382 polypeptides'2008 7,375,179'PRO19680 polypeptides'2008 7,375,196'PRO19814 antibodies'2008 7,371,815'PRO19644 polypeptides'2008 7,371,824'PRO6093 polypeptides'2008 7,371,816'PRO10284 polypeptides'2008 7,371,836'PRO526 nucleic acids'2008 7,371,814'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,371,827'Antibodies against the PRO1126 polypeptide'2008 7,371,817'PRO9783 polypeptides'2008 7,368,558'PRO357 nucleic acids'2008 7,368,250'Compositions and methods for the diagnosis and treatment of tumor'2008 7,365,157'PRO9912 polypeptides'2008 7,365,156'PRO1316 polypeptides'2008 7,361,732'PRO4400 polypeptides'2008 7,361,337'Antibodies against the PRO1754 polypeptides'2008 7,358,340'PRO19563 antibodies'2008 7,357,926'Antibodies against PRO1879 and the use thereof'2008 7,358,339'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,355,013'PRO6017 antibodies'2008 7,355,007'Antibodies that bind PRO5005 Polypeptides'2008 7,354,999'PRO1481 polypeptides'2008 7,354,997'Polypeptide encoded by a nucleic acid underexpressed in stomach tumor'2008 7,355,006'Antibodies against the PRO1271 polypeptides'2008 7,355,002'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,355,000'PRO1380 polypeptides'2008 7,354,998'PRO7171 polypeptides'2008 7,351,794'PRO1754 polypeptides'2008 7,351,796'PRO9904 polypeptides'2008 7,351,793'PRO1286 polypeptide'2008 7,351,795'PRO19563 polypeptides'2008 7,351,804'Antibodies against PRO4421'2008 7,351,543'Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma'2008 7,351,789'PRO19624 polypeptides'2008 7,351,802'PRO19672 antibodies'2008 7,348,405'PRO10274 polypeptides'2008 7,348,415'PRO1316 antibodies'2008 7,348,414'Antibodies against the PRO1154 polypeptide'2008 7,344,880'Nucleic acid encoding PRO9912 polypeptides'2008 7,345,146'PRO1271 Polypeptides'2008 7,345,145'Secreted and transmembrane polypeptides and nucleic acids encoding the same'2008 7,345,147'PRO16089 polypeptides'2008 7,343,721'PRO4406 polypeptide'2008 7,342,104'Antibodies against the PRO4320 polypeptide'2008 7,342,097'PRO1309 polypeptides'2008 7,342,098'PRO1154 polypeptide'2008 7,342,096'PRO1879 polypeptide'2008 7,339,034'PRO1305 antibodies'2008 7,339,025'PRO6246 polypeptides'2008 7,339,024'PRO1772 polypeptides'2008 7,339,033'PRO1481'2008 7,335,740'Antibodies against the PRO7434 polypeptides'2008 7,335,731'PRO4332 polypeptides'2008 7,335,730'PRO7436 polypeptides'2008 7,335,732'PRO9799 polypeptides'2008 7,335,728'PRO1310 polypeptides'2008 7,335,746'Anti-pro4976 antibodies'2008 7,335,729'PRO4320 polypeptide'2008 7,335,745'Antibodies against the PRO4403 polypeptides'2008 7,332,573'PRO1571 polypeptides'2008 7,332,583'PRO19628 Antibodies'2008

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2018Patents assigned to GENENTECH INC (635)· patent assignee history

1999–2018Based in Belmont, CA, US· patent location history

2002Based in South San Francisco, CA, US· patent location history

2006–2021Based in San Francisco, CA, US· patent location history

2010–2021Patents assigned to ONCOMED PHARM INC (78)· patent assignee history

2011–2015Patents assigned to GURNEY AUSTIN L (24)· patent assignee history

2011–2017Patents assigned to GURNEY AUSTIN (15)· patent assignee history

2011–2013Patents assigned to GODDARD AUDREY (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
GENENTECH INC	635	1999–2018
ONCOMED PHARM INC	78	2010–2021
GURNEY AUSTIN Lself	24	2011–2015
GURNEY AUSTINself	15	2011–2017
GODDARD AUDREY	10	2011–2013

Locations

Location	Patents	Span
Belmont, California, US	619	1999–2018
San Francisco, California, US	98	2006–2021
South San Francisco, California, US	1	2002